Central and East European Oncology Group

  • Members
    Members

    CEEOG has greatly expanded and now includes 35 academic andcommunity hospitals from Poland, Romania, Slovakia, Bulgaria, Slovenia, Croatia, Bosnia and Hercegovina, Yugoslavia, Hungary, Czech Republic and Russia.

     

     

     

Polish Brain Metastasis Consortium

pbmc-logo

The group was founded in 2005 by Dr. Renata Duchnowska from the Military Medical Institute in Warsaw as a result of establishing an informal network of some Polish oncology centers. A year later group teamed up with foreign research groups and academic centers. In 2008, the patronage of the Group's research covered the CEEOG.

CEEOG: Central and East European Oncology Group

Historically, CEEOG was established in 1983 as the South and East European Oncology Group (SEEOG) and chaired for the next 16 years by Prof. Sandor Eckhardt from the National Cancer Institute in Budapest. SEEOG was a modern drug-oriented research organization. Its major aim was to conduct phase II and III clinical trials of novel anticancer agents and regimens in common malignancies. Group meetings were held regularly twice a year and were attended by the representatives of all institutions. These were typically working sessions at which new study protocols were proposed and discussed, and the progress of ongoing studies was presented. Data collection was greatly facilitated by user-friendly bilingual case report forms and by the computerization of the Trial Center. The goal of SEEOG was to identify, evaluate and introduce new anticancer agents.

In the mid-80s, the SEEOG consisted of 15 institutions from Hungary, Poland, Czechoslovakia, Yugolavia, Bulgaria and Romania. After a few years it was renamed the Central and East European Oncology Group (CEEOG), as this corresponded better to the geographical location of its member countries. In the 80s and early 90s the Group conducted a series of trials addressing breast cancer, ovarian cancer, lung cancer and head and neck cancer.

Due to financial and organizational constraints, the size of particular trials has been limited to an average of around 100 patients per study. Most of the participating institutions were academic hospitals. In studies in which tumor response was among the main interests, there was an extramural review of imaging records. The trials were carried out according to high scientific standards and GCP requirements. Knowledge about how to conduct good trials was disseminated by the Group to all participating countries.

CEEOG has greatly expanded and now includes 35 academic andcommunity hospitals from Poland, Romania, Slovakia, Bulgaria, Slovenia, Croatia, Bosnia and Hercegovina, Yugoslavia, Hungary, Czech Republic and Russia. A few other centers have recently applied for membership. The data management within CEEOG has been delegated to a clinical research organization, whereas the sponsoring company staff has conducted monitoring. Recent expansion of the Group will hopefully allow it to perform larger clinical trials.

In 1999, chairmanship of the CEEOG was handed over to Prof. Jacek Jassem from the Medical University of Gdańsk, Poland. Gdańsk was chosen as the venue of the new Data Center, which is financed by the sponsored studies performed by the CEEOG. Most of the funds are distributed directly to the participating institutions. Of the completed trials most attention has been given to the International Exemestane Study (IES), in which CEEOG has contributed with the highest number of accrued patients from the 27 cooperative groups, participating in this enterprise (New England Journal of Medicine). Recently CEEOG has developed and activated a new protocol in non-small cell lung cancer. CEEOG, within cooperation with Breast Intergroup (BIG), will also take part in a series of forthcoming large intergroup phase III studies in breast cancer, including important pivotal trials. Future plans include extending clinical activity to surgery and radiotherapy.

CONTACT

Home
 
Medical University of Gdańsk
Department of Oncology and Radiotherapy
7 Dębinki Street
80-211 Gdańsk, Poland 
 
email
Phone: +48 58 349 2282
Fax: +48 58 349 22 44
E-mail: Ten adres pocztowy jest chroniony przed spamowaniem. Aby go zobaczyć, konieczne jest włączenie obsługi JavaScript.